Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Dynavax Shareholder Alert: Briscoe Law and Powers Taylor Investigate Possible Breaches of Fiduciary Duty by Officers and



  Dynavax Shareholder Alert: Briscoe Law and Powers Taylor Investigate
  Possible Breaches of Fiduciary Duty by Officers and Directors

Business Wire

DALLAS -- June 21, 2013

Former United States Securities and Exchange Commission attorney Willie
Briscoe, founder of The Briscoe Law Firm, PLLC, and the securities litigation
firm of Powers Taylor, LLP announce that a federal class action lawsuit has
been filed against Dynavax Technologies Corporation (“Dynavax” or “Company”)
(Nasdaq: DVAX). The firms are investigating additional legal claims against
the officers and directors of Dynavax during the period of April 26, 2012 and
June 10, 2013 (the “Class Period”).

If you are an affected investor and you want to learn more about the lawsuit
or join the action, contact Willie Briscoe at The Briscoe Law Firm, PLLC,
(214) 239-4568, or via email at WBriscoe@TheBriscoeLawFirm.com, or Zachary
Groover at Powers Taylor, LLP, toll free (877) 728-9607, via email at
zach@powerstaylor.com. There is no cost or fee to you.

In a recently filed federal class action complaint, Dynavax and certain of its
officers and directors were charged with violating certain provisions of the
Securities Exchange Act of 1934. Specifically, the complaint alleges that
among other things, defendants’ misrepresented and/or failed to disclose that:
(a) the clinical trial for HEPLISAV was flawed since the trial demographics
did not represent the population of the United States; (b) the trial did not
have a one-year safety follow-up, which is typically required for vaccines;
(c) the trial lacked information concerning concomitant use with other
vaccines; (d) given the novel adjuvant that the HEPLISAV vaccine contains, the
clinical trial for HEPLISAV was flawed because the safety database size was
inadequate to rule out rare adverse autoimmune events; (e) Dynavax failed to
provide the FDA with sufficient data concerning its manufacturing processes
and controls for HEPLISAV on its BLA; and (f) as a result of the above, the
Company’s positive statements about the Company’s outlook, including the
statements about its launch of HEPLISAV in 2013, were materially false or
misleading. According to the complaint, when the true facts were revealed, the
Company’s shares dropped 73% from their Class Period high.

Shareholder rights attorney Willie Briscoe said, “Recent revelations about
alleged improper business practices and procedures regarding key aspects of
Dynavax’s business and other misleading financial statements have prompted the
firms to investigate possible breaches of fiduciary duties and other
violations of state law by Dynavax’s officers and directors. Based on our
investigation, we are prepared to pursue litigation to preserve the company
and the value of Dynavax stock for all shareholders.”

The Briscoe Law Firm, PLLC is a full service business litigation, commercial
transaction, and public advocacy firm with more than 20 years of experience in
complex litigation and transactional matters.

Powers Taylor, LLP is a boutique litigation law firm that handles a variety of
complex business litigation matters, including claims of investor and
stockholder fraud, shareholder oppression, shareholder derivative suits, and
security class actions.

Contact:

The Briscoe Law Firm, PLLC
Willie Briscoe, 214-239-4568
WBriscoe@TheBriscoeLawFirm.com
or
Powers Taylor, LLP
Zachary Groover, 877-728-9607
zach@powerstaylor.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement